Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Antimicrob Agents Chemother. 2011 Mar;55(3):1308-11. doi: 10.1128/AAC.01325-10. Epub 2010 Dec 28.
Fifty-six serum posaconazole trough levels were measured in 17 cardiothoracic transplant recipients. Initial levels were ≤ 0.5, 0.51 to 0.99, and ≥ 1 μg/ml for 47, 29, and 24% of patients, respectively. Median trough levels associated with therapeutic success were higher than those associated with failure (1.55 versus 0.34 μg/ml; P = 0.006). Patients with levels consistently >0.5 μg/ml were more likely to have successful outcome (P = 0.055). Age ≥ 65 years, oral administration, and absence of proton pump inhibitors were associated with higher levels of posaconazole (P = 0.006, 0.006, and 0.001, respectively).
在 17 例心胸器官移植受者中测量了 56 份泊沙康唑血药谷浓度。初始浓度分别为 47%、29%和 24%的患者的浓度值为 ≤ 0.5μg/ml、0.51 至 0.99μg/ml 和≥1μg/ml。与治疗成功相关的血药谷浓度中位数高于与治疗失败相关的浓度中位数(1.55μg/ml 比 0.34μg/ml;P=0.006)。浓度持续>0.5μg/ml 的患者更有可能获得成功的治疗结果(P=0.055)。年龄≥65 岁、口服给药和无质子泵抑制剂与泊沙康唑浓度升高相关(P=0.006、0.006 和 0.001)。